The Minneapolis-based gBETA Medtech accelerator program today announced the five companies participating in its spring 2021 cohort.
The startups hail from across the U.S. and aim to improve patient care through devices, software and care management.
The spring 2021 cohort includes:
- Rhaeos, whose FlowSense wearable skin patch is a thermal flow sensor that is mounted on a hydrocephalus patient’s skin overlying the shunt to detect shunt flow. Rhaeos has raised $2.3 million, received FDA breakthrough designation, published clinical data in Science and Nature, and is on track for initial market entry in Q1 2022, according to gBETA.
- OpalGenix, which developed patented genotype-based opioid risk prediction and clinical decision support software, GPS-Opioid, to help doctors personalize therapy for patients who require opioids for pain.
- Breathe99, whose B2 Mask offers industrial-grade protection against infectious diseases, wildfire smoke and ambient air pollution. The B2 Mask’s patent-pending design offers an ergonomic face seal and uses high-efficiency filters. Breathe99 has logged more than $1.5 million in sales since April 2020.
- UptimeHealth, which has developed medical equipment management software in an online platform to simplify medical equipment service events, purchases and compliance. UptimeHealth has more than150 healthcare facilities and over 1,300 technicians on the platform, and has generated $150,000 in sales since launching in 2018.
- Xtraction Corp, whose patented sleeve technology is deigned to enable surgeons to remove large specimens or organs from small incisions in order to reduce procedure time and improve patient recovery.
gBETA Medtech is a free, seven-week accelerator that works with medical devices, healthcare-related software, biotech and diagnostics startups for no fees and no equity. Participants receive intensive, individualized coaching and access to gener8tor’s national network of mentors, customers, corporate partners and investors.
This year’s spring cohort members were chosen from among more than 170 applicants.
“In the last year, we’ve seen the number of applicants triple,” said Oscar Brooks, senior upstream product manager at program sponsor Boston Scientific, in a news release. “We look for startup companies and individuals who are eager to unlock new opportunities to transform patient care and uncover meaningful innovations that will make a difference for patients around the world.”